Kala Pharmaceuticals Reports Second Quarter 2018 Financial Results
WALTHAM, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of therapies using its proprietary mucus-penetrating particle (MPP) technology with an initial focus on the treatment of eye diseases, today reported financial results for the second quarter ended June 30, 2018. "Since our last update we have made excellent progress,” said Mark Iwicki, Chairman and Chief Executive Officer. “We have defined our s